Replies to post #155535 on Cytodyn Inc (CYDY)

[Bourbon_on_my_cornflakes]

Patients were 5x more likely to be alive at day 14 if they received ler0nlimab than SoC only.

Upon further statistical analysis, it was revealed that when leronlimab was added to standard of care (SoC), mortality at 14 days decreased by 82% (p=.0233, N=62).

Furthermore, leronlimab administration was associated with a 400% improvement in the ranking on the 7-point ordinal scale at 14 days when given in conjunction with SoC (p=.021, N=62).

“We will expediently submit an update with the above 14-day benefit to the U.S. FDA, Health Canada, and MHRA and will work closely with regulators in other countries. The Company believes this new information bolsters the case for immediate use of leronlimab for critically ill patients,” commented Nader Pourhassan, Ph.D., President and CEO.